Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F12%3A43903526" target="_blank" >RIV/00216208:11120/12:43903526 - isvavai.cz</a>
Alternative codes found
RIV/00064173:_____/12:43903526
Result on the web
<a href="http://dx.doi.org/10.1111/j.1469-0691.2012.03784.x" target="_blank" >http://dx.doi.org/10.1111/j.1469-0691.2012.03784.x</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/j.1469-0691.2012.03784.x" target="_blank" >10.1111/j.1469-0691.2012.03784.x</a>
Alternative languages
Result language
angličtina
Original language name
Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients
Original language description
A prospective, multicentre, phase IIIb study with an exploratory, open-label design was conducted to evaluate efficacy and safety of anidulafungin for the treatment of candidaemia/invasive candidiasis (C/IC) in specific ICU patient populations. . Patients received anidulafungin (200 mg on day 1, 100 mg/day thereafter) for 10-42 days, optionally followed by oral voriconazole/fluconazole. The primary efficacy endpoint was global (clinical and microbiological) response at the end of all therapy (EOT). Secondary endpoints included global response at the end of intravenous therapy (EOIVT) and at 2 and 6 weeks post-EOT, survival at day 90, and incidence of adverse events (AEs). The primary efficacy analysis was performed in the modified intent-to-treat (MITT) population, excluding unknown/missing responses. The safety and MITT populations consisted of 216 and 170 patients, respectively. The most common pathogens were Candida albicans (55.9%), C. glabrata (14.7%) and C. parapsilosis (10.0%).
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FN - Epidemiology, infection diseases and clinical immunology
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Clinical Microbiology and Infection
ISSN
1198-743X
e-ISSN
—
Volume of the periodical
18
Issue of the periodical within the volume
7
Country of publishing house
GB - UNITED KINGDOM
Number of pages
8
Pages from-to
680-687
UT code for WoS article
000305285200024
EID of the result in the Scopus database
—